In October, the Centers for Medicare and Medicaid Services directed carriers to again include three biologics in Medicare Part B coverage. (posted Nov. 19)
Search results for: Biologics
Meet the Model Biologics Policy
At its February meeting, the ACR board of directors approved the Model Biologics Policy, which will be used when discussing guidelines and patients’ quality of treatment with health insurance companies.
Integrating Immunology and Biologics into Clinical Practice
With the rapid expansion of new classes of medications, clinical practice has changed dramatically, and rheumatology health professionals must have a fundamental knowledge of immunology and the mechanisms of action of the biologic agents that have emerged with this expansion. Familiarity with the predrug screening recommended for biologic agents and the appropriate safety and disease monitoring necessary when a person uses these products is essential for the best patient outcomes. Additionally, being able to obtain drug plan authorization for use of biologics and being able to educate patients and their families or support team members about the financial considerations of these drugs helps to ensure best rheumatology practice.
Managing Office Infusions: From Biologics to Bones
On June 9, Josh Brinks, BSN, MSN, FNP, will address the management of office infusions during the ARHP June audioconference/webcast.
ACR-Led Resolutions Supporting Research Funding, Biosimilars Access Advance at Annual AMA House of Delegates Meeting
An ACR-led resolution that calls for the protection of NIH funding and the ability to negotiate indirect costs will become AMA policy, along with several other resolutions supported by the ACR.
FDA Approves Upadacitinib for GCA
Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
Incarcerated Individuals with Rheumatic Conditions
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
Trials Find Potential Treatments for SLE, Lupus Nephritis
In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…
Belimumab Promising for Children with Lupus Nephritis
In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…
How to Recognize Inborn Errors of Immunity
Inborn errors of immunity may not always be easy to recognize, but rheumatologists should look out for them. Dr. Bharat Kumar shares his insights.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 75
- Next Page »